Medical Licensing (MD/DO) · Independent exam preparation
Pulmonary Disease Certification Examination: Clinical Reasoning Guide Study Guide
Practise pulmonary diagnosis, pharmacotherapy, ventilation, sleep treatment, infection management, and cancer staging with 60 focused concepts and 20 explained clinical questions.
By CertMedbry · Updated 18 October 2026
Practise selecting diagnostic tests, interpreting discordant findings, protecting injured lungs, and choosing interventions that change patient outcomes. These 60 selective concepts cover all 13 domains of ABIM's April 2026 certification blueprint. The official outline defines the full examination scope, including important topics beyond this guide.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification examination does this guide cover?
The American Board of Internal Medicine Pulmonary Disease Certification Examination. This is physician subspecialty board certification, distinct from initial medical licensure and ABIM Critical Care Medicine certification. The catalog label “ABIM - Subspecialty in Pulmonary Disease” refers to this examination.
How many questions are administered, and which contribute to the score?
The April 2026 certification blueprint describes up to 240 single-best-answer multiple-choice questions. Approximately 40 are new questions that do not count toward the examinee's score. Because both figures are qualified, they should not be converted into a guaranteed exact number of scored questions.
Pulmonary Disease Blueprint: Certification Examination (CERT), April 2026
What question styles and clinical media can appear?
Most questions present patient scenarios and assess diagnosis, test selection and interpretation, treatment, prognosis, epidemiology, or clinically relevant pathophysiology. Clinical findings may include photographs, radiographs, electrocardiograms, heart or lung sounds, video, and other media. Most radiographic and histologic images can be enlarged.
Pulmonary Disease Blueprint: Certification Examination (CERT), April 2026
What should I verify about duration, delivery, breaks, and adaptivity?
Use current ABIM examination-day and appointment instructions to confirm session duration, breaks, and delivery arrangements. The certification blueprint establishes the question format but does not specify these scheduling details or describe an adaptive testing algorithm.
Pulmonary Disease Blueprint: Certification Examination (CERT), April 2026 · ABIM: Pulmonary Disease Certification Policies
Which blueprint version applies, and does it have a separate effective date?
This guide follows the certification blueprint dated April 2026, verified as the current certification-directory link on October 9, 2026. The document states no separate effective date. ABIM reviews its blueprint annually and notes that actual examination content may vary.
ABIM: Blueprints · Pulmonary Disease Blueprint: Certification Examination (CERT), April 2026
Does the future expanded blueprint replace this outline?
ABIM lists Pulmonary Disease for expanded-blueprint publication in January 2028 and certification implementation in fall 2028. That future rollout does not replace the April 2026 certification outline used for this guide. Certification and maintenance-of-certification blueprints are listed separately.
How is the official examination content weighted?
The typical examination allocations are Obstructive Lung Disease 17.5%; Critical Care Medicine 15%; Diffuse Parenchymal Lung Disease (DPLD) 10%; Sleep Medicine, Neuromuscular and Skeletal 10%; Epidemiology 2%; Infections 12%; Neoplasia 9.5%; Pleural Disease 5%; Quality, Safety, and Complications 5%; Transplantation 2%; Vascular Diseases 6%; Respiratory Physiology and Pulmonary Symptoms 4%; and Occupational and Environmental Diseases 2%. The short learning sets emphasize larger domains while preserving coverage of every domain; they do not reproduce these percentages exactly.
Pulmonary Disease Blueprint: Certification Examination (CERT), April 2026
How should I use the questions and flashcards?
Use the 20 independent four-option questions to explain a clinical decision and reject each alternative. Use the 20 flashcards for active recall between case sessions. Neither set reproduces a complete examination or predicts a passing result.
Pulmonary Disease Blueprint: Certification Examination (CERT), April 2026
Preparation for ABIM's physician subspecialty certification in pulmonary disease. The questions and flashcards are independently authored educational material, without ABIM endorsement.
Outline used: ABIM Pulmonary Disease Blueprint, Certification Examination (CERT), dated April 2026 and currently linked from ABIM's certification blueprint directory; verified on 2026-10-09. The document does not state a separate effective date. The workbook label 'ABIM - Subspecialty in Pulmonary Disease' maps to ABIM's officially named Pulmonary Disease Certification Examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Obstructive Lung Disease17.5%
1.What objective findings support an asthma diagnosis?
Asthma combines a characteristic history of variable respiratory symptoms with evidence of variable expiratory airflow limitation. GINA 2026 adult criteria include an increase in FEV1 or FVC of at least 12% and 200 mL from baseline after bronchodilator, or average daily peak expiratory flow variability greater than 10% over two weeks. These findings support asthma in the appropriate clinical context; neither is uniquely specific for asthma. A single normal test does not exclude an intermittent disorder. Establish objective variability before long-term controller treatment when feasible, because treatment can make subsequent confirmation harder.
Apply it
An adult's FEV1 increases from 2.00 L to 2.30 L after bronchodilator. The increase is 300 mL and 15% of baseline, meeting the adult reversibility criterion and supporting asthma when the symptom history is compatible.
Common pitfall: Both the percentage and absolute-volume criteria must be met for this bronchodilator criterion. Wheeze or subjective improvement alone does not establish asthma.
GINA 2026 Summary Guide for Asthma Management and Prevention
2.When does normal spirometry warrant further asthma testing?
Airflow obstruction may be absent between asthma episodes. With a convincing history, repeat spirometry during symptoms, measure morning and evening peak flow for two weeks, or consider bronchial provocation. Calculate each day's peak-flow variability as the highest minus lowest reading divided by their mean, multiplied by 100; then average the daily percentages. Average variability greater than 10% supports asthma in adults. Use the same meter and consistent technique. Provocation assesses airway hyperresponsiveness and must be interpreted with symptoms and competing diagnoses. Bronchodilators and anti-inflammatory treatment can reduce test sensitivity.
Apply it
A peak-flow diary averages 14% daily variability over two weeks despite normal office spirometry. This provides objective support for variable airflow limitation in an adult with compatible episodic symptoms.
Common pitfall: A positive challenge is not synonymous with asthma. Do not calculate diary variability from only the single highest and lowest readings across the entire fortnight.
GINA 2026 Summary Guide for Asthma Management and Prevention
3.What should be checked before escalating asthma treatment?
Persistent symptoms do not automatically indicate treatment-resistant airway inflammation. Confirm the diagnosis, observe inhaler technique, assess adherence, and identify relevant exposures and comorbidities before stepping up therapy. Poor medication delivery can imitate pharmacologic failure. Distinguish current symptom burden from future exacerbation risk, because a patient with few daily symptoms may still have substantial risk. Correcting an inhaler error or an access barrier can change control without increasing medication intensity.
Apply it
A patient prescribed an inhaled corticosteroid–long-acting bronchodilator reports daily symptoms. Watching an inhalation reveals failure to load the device. Teach the technique and reassess control before labeling the asthma severe.
Common pitfall: Escalating medication without checking actual use can increase treatment burden while leaving the principal cause of poor control completely unchanged and unrecognized.
GINA 2026 Summary Guide for Asthma Management and Prevention
4.How does maintenance-and-reliever therapy link symptom relief to anti-inflammatory treatment?
Maintenance-and-reliever therapy uses a suitable inhaled corticosteroid–formoterol combination for both scheduled maintenance and symptom relief. Formoterol provides rapid bronchodilation, while each reliever use also delivers corticosteroid during worsening airway inflammation. The regimen depends on the specific combination and treatment step; it is not a property of every corticosteroid–long-acting bronchodilator inhaler. Education must distinguish maintenance use, symptom-driven use, and the action-plan threshold for urgent assessment.
Apply it
An adult using an appropriate corticosteroid–formoterol maintenance regimen asks which inhaler to use for breakthrough symptoms. Review whether the prescribed plan is maintenance-and-reliever therapy and demonstrate its symptom-driven instructions.
Common pitfall: Do not substitute a salmeterol-containing combination as the reliever component; the evidence-based strategy depends on a suitable rapidly acting formoterol combination.
GINA 2026 Summary Guide for Asthma Management and Prevention
5.How should type 2 biomarkers influence asthma decisions?
Blood eosinophils and fractional exhaled nitric oxide can support identification of type 2 airway inflammation and help characterize difficult asthma. They do not independently diagnose asthma or prove that symptoms arise from uncontrolled asthma. Results vary with corticosteroid exposure and other clinical factors. Interpret biomarkers after confirming the diagnosis and addressing modifiable treatment problems. In established severe asthma, phenotype assessment helps guide consideration of targeted therapies and relevant eligibility criteria.
Apply it
A patient with recurrent exacerbations has elevated eosinophils but inconsistent controller use. First optimize adherence and inhaler delivery; then reassess persistent disease and inflammatory phenotype before selecting a targeted treatment pathway.
Common pitfall: An elevated eosinophil count is not a shortcut around diagnostic confirmation; alternative eosinophilic disorders and treatment effects can alter its clinical meaning.
GINA 2026 Summary Guide for Asthma Management and Prevention
6.Which clues suggest inducible laryngeal obstruction, and how is it documented?
Inducible laryngeal obstruction produces transient inappropriate laryngeal narrowing and can mimic or coexist with asthma. Abrupt throat tightness, inspiratory noise, and symptoms at peak exercise raise suspicion. Document the obstruction with laryngoscopy during symptoms or an appropriate provocation. For exercise-triggered episodes, continuous laryngoscopy during exercise visualizes laryngeal behavior throughout the provoking activity. Because narrowing is intermittent and may resolve rapidly, an asymptomatic examination can be normal. These diagnostic principles are described in the [official ERS/European Laryngological Society statement](https://doi.org/10.1183/13993003.02221-2016).
Apply it
A runner develops inspiratory noise at peak exertion and recovers rapidly after stopping. Arrange continuous laryngoscopy during exercise rather than relying on a normal resting laryngeal examination.
Common pitfall: Calling every respiratory noise wheeze can obscure an upper-airway problem. Normal laryngoscopy between episodes does not exclude inducible obstruction, and coexisting asthma requires separate assessment.
GINA 2026 Summary Guide for Asthma Management and Prevention · eilo.pdf
7.Which findings make an asthma exacerbation immediately dangerous?
An asthma exacerbation becomes especially concerning when airflow limitation threatens ventilation or the patient shows exhaustion. Drowsiness, confusion, a silent chest, or worsening respiratory effort require urgent escalation and close monitoring. A quiet chest can reflect critically reduced airflow rather than improvement. Assess speech, respiratory rate, oxygenation, pulse, and lung function when feasible, while beginning treatment promptly. Serial reassessment is essential because the trajectory may matter more than one initial measurement.
Apply it
A previously agitated patient with severe asthma becomes drowsy and has barely audible breath sounds despite ongoing treatment. Treat this as impending respiratory failure and obtain immediate advanced airway and critical care support.
Common pitfall: A decrease in wheezing is reassuring only when accompanied by improved airflow and clinical status; exhaustion can make a deteriorating patient sound quieter.
GINA 2026 Summary Guide for Asthma Management and Prevention
8.When should oxygen be prescribed in stable COPD, and for how long?
ATS recommends long-term oxygen for at least 15 hours daily in COPD with severe chronic resting room-air hypoxemia: PaO2 at or below 55 mm Hg or SpO2 at or below 88%; alternatively, PaO2 56–59 mm Hg or SpO2 89% with edema, hematocrit at least 55%, or P pulmonale. Confirm chronicity in a stable state and reassess oxygen started during an exacerbation. Routine long-term oxygen is not suggested for moderate resting hypoxemia, SpO2 89–93%, without severe-hypoxemia qualifying features. Ambulatory oxygen is conditionally suggested for severe exertional hypoxemia, generally SpO2 at or below 88%, but this does not establish the survival benefit associated with severe resting hypoxemia. These are clinical recommendations; jurisdiction-specific reimbursement requirements are separate.
Apply it
Repeated stable room-air PaO2 of 53 mm Hg supports oxygen for at least 15 hours daily. Resting SpO2 of 95% with reproducible walking desaturation to 86% instead prompts an individualized ambulatory oxygen assessment.
Common pitfall: Brief intermittent oxygen use is not the recommended long-term regimen for severe chronic resting hypoxemia. Dyspnea alone does not establish an oxygen indication.
Home Oxygen Therapy for Adults with Chronic Lung Disease: Official ATS Clinical Practice Guideline
9.How should persistent dyspnea guide stable COPD bronchodilator treatment?
For COPD with dyspnea or exercise intolerance, ATS recommends combined long-acting beta2-agonist and long-acting muscarinic antagonist therapy over either agent alone. The two classes provide bronchodilation through complementary pathways: beta2-receptor stimulation and inhibition of muscarinic bronchoconstriction. Before escalation, observe inhaler technique and assess adherence so that inadequate delivery is not mistaken for medication failure. Persistent symptoms also warrant consideration of cardiac disease, deconditioning, and other causes of exercise limitation. This is a symptom-directed maintenance decision, distinct from selecting anti-inflammatory treatment to prevent exacerbations. See the [ATS pharmacologic guideline](https://doi.org/10.1164/rccm.202003-0625ST).
Apply it
A patient remains breathless on correctly used LAMA monotherapy. Consider LABA/LAMA treatment, assess other contributors to limitation, and reassess symptoms and activity after the change.
Common pitfall: Persistent dyspnea alone does not establish a need for inhaled corticosteroids or supplemental oxygen. Exacerbation history and documented oxygenation abnormalities answer different treatment questions.
10.When does adding inhaled corticosteroid become reasonable in stable COPD?
ATS conditionally supports ICS/LABA/LAMA over LABA/LAMA for symptomatic COPD with at least one exacerbation in the past year requiring antibiotics, oral corticosteroids, or hospitalization despite dual bronchodilator therapy. Adding ICS can reduce exacerbations while increasing pneumonia risk. This tradeoff makes the recommendation conditional and requires an individualized assessment of exacerbation burden, pneumonia risk, treatment preferences, and effective use of existing bronchodilators. Eosinophilia without an exacerbation history does not independently establish the indication. Maintenance oral corticosteroids are discouraged. See the [ATS pharmacologic guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC7193862/).
Apply it
A patient has recurrent treated exacerbations despite correctly used LABA/LAMA. Consider triple therapy after confirming adherence and inhaler technique, reviewing prior pneumonia and the exacerbation pattern, and discussing the expected reduction in exacerbations against the increased pneumonia risk.
Common pitfall: Isolated breathlessness or eosinophilia does not substitute for the exacerbation history supporting ICS addition. Discuss pneumonia explicitly when assessing the benefits and harms of triple therapy.
11.Why can incomplete exhalation worsen obstructive respiratory failure?
Expiratory flow limitation can prevent complete lung emptying before the next breath begins. Trapped gas raises end-expiratory lung volume and creates intrinsic positive end-expiratory pressure, increasing the effort needed to initiate inspiration. Rapid breathing can aggravate this cycle by shortening expiratory time. The mechanism helps explain why severe obstruction may produce marked work of breathing and hypercapnia. Ventilatory support must account for expiratory mechanics rather than focusing only on the respiratory rate.
Apply it
During a COPD exacerbation, a patient becomes increasingly tachypneic with prolonged expiration and rising PaCO2. Recognize worsening ventilatory mechanics, assess respiratory acidosis, and evaluate suitability for closely monitored bilevel noninvasive ventilation support.
Common pitfall: Treating tachypnea as proof of adequate ventilation overlooks ineffective rapid breathing; respiratory effort can increase while alveolar ventilation and gas exchange progressively deteriorate.
Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure
Critical Care Medicine15%
12.Why are ARDS tidal volumes based on predicted body weight?
Lung size relates more closely to height and sex than to actual body mass. ARDS ventilation therefore uses predicted body weight to select a protective tidal volume, generally within 4–8 mL/kg, with approximately 6 mL/kg as a common starting target. Using actual weight in obesity can expose the functional lung to excessive stretch. Calculate predicted body weight first, then reassess plateau pressure and gas exchange rather than accepting a convenient default ventilator volume.
Apply it
A patient with predicted body weight of 60 kg and actual weight of 110 kg develops ARDS. A starting tidal volume near 360 mL follows the 6 mL/kg predicted-weight approach; 660 mL would use the wrong denominator.
Common pitfall: Actual body weight can substantially overestimate an appropriate tidal volume in obesity; a numerically familiar ventilator setting is not evidence of lung protection.
ATS/ESICM/SCCM Guideline: Mechanical Ventilation in Adult Patients with ARDS · ATS 2024 Clinical Year in Review
13.What does plateau pressure add to ARDS ventilator assessment?
Plateau pressure estimates the pressure remaining after inspiratory flow stops during an appropriate hold in a passive patient. It differs from peak pressure, which also includes flow-dependent airway resistance. ARDS lung-protective ventilation targets plateau pressure below 30 cm H2O while using low tidal volumes. A high peak pressure with a lower plateau suggests a different problem from elevation of both pressures. Interpretation requires attention to patient effort and chest-wall mechanics.
Apply it
An intubated patient has peak pressure of 42 cm H2O but plateau pressure of 25 cm H2O. Investigate increased airway resistance, including secretions or bronchospasm, rather than equating peak pressure directly with alveolar distending pressure.
Common pitfall: An inspiratory hold during active respiratory effort may produce a misleading plateau measurement; verify measurement conditions before using the number to change ventilation.
ATS/ESICM/SCCM Guideline: Mechanical Ventilation in Adult Patients with ARDS
14.When does prone positioning become a major ARDS intervention?
For severe ARDS, prolonged prone positioning is recommended for more than 12 hours daily. Proning redistributes ventilation and mechanical stress and can improve ventilation-perfusion matching. It complements low tidal volume ventilation rather than replacing it. The intervention requires an organized team to protect the airway, vascular access, pressure points, and eyes. A transient oxygenation response is useful information, but the decision rests on the severe ARDS context and a complete protective strategy.
Apply it
A patient with severe ARDS remains markedly hypoxemic despite lung-protective ventilation. Mobilize a trained team for prolonged prone positioning while maintaining appropriate tidal volume, pressure monitoring, and secure airway and line management.
Common pitfall: Briefly turning a patient prone for an oxygenation check is not equivalent to the prolonged positioning strategy studied and recommended for severe ARDS.
ATS/ESICM/SCCM Guideline: Mechanical Ventilation in Adult Patients with ARDS · ATS 2024 Clinical Year in Review
15.How can PEEP improve oxygenation while creating circulatory risk?
Positive end-expiratory pressure can maintain aeration of recruitable lung units and reduce repetitive opening and closure. Its benefit depends on recruitment outweighing overdistension. Higher intrathoracic pressure can reduce venous return, and excessive lung inflation can increase right ventricular load. The ARDS ventilation guideline conditionally supports higher PEEP in moderate or severe ARDS. Evaluate oxygenation, pressure measurements, and hemodynamics together; improved saturation alone does not demonstrate that a PEEP change is beneficial overall.
Apply it
After a PEEP increase, oxygenation improves but blood pressure falls and signs of right ventricular strain appear. Reassess the net physiologic effect rather than continuing escalation solely because the saturation is higher.
Common pitfall: PEEP is not uniformly recruiting: the same pressure increase can open some lung units while overdistending others and impairing circulation in the same patient.
ATS/ESICM/SCCM Guideline: Mechanical Ventilation in Adult Patients with ARDS
16.When is bilevel noninvasive ventilation indicated during a COPD exacerbation?
Bilevel noninvasive ventilation is recommended for acute or acute-on-chronic respiratory acidosis caused by a COPD exacerbation. The key pattern is hypercapnia with pH at or below 7.35 and ongoing respiratory distress despite standard treatment. Pressure support assists ventilation and can reduce respiratory muscle workload. Selection also requires assessment of airway protection, cooperation, secretions, and hemodynamic stability. Treatment belongs in a setting capable of close reassessment and prompt intubation if the patient deteriorates.
Apply it
An alert patient with a COPD exacerbation has pH 7.28, PaCO2 68 mm Hg, and persistent tachypnea after initial therapy. Begin closely monitored bilevel noninvasive ventilation if airway protection and other clinical conditions permit.
Common pitfall: Hypercapnia without respiratory acidosis is not the same evidence-based indication; interpret PaCO2 with pH, baseline physiology, respiratory effort, and the overall clinical trajectory.
Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure
17.Which changes signal that a noninvasive ventilation trial is failing?
An appropriate noninvasive ventilation trial requires early reassessment of respiratory rate, work of breathing, mental status, oxygenation, and acid-base status. Improvement in pH and respiratory distress supports continuation. Worsening acidosis, exhaustion, inability to protect the airway, or deteriorating consciousness suggests failure and demands prompt reconsideration of invasive support. More severe initial acidosis raises failure risk. Noninvasive support should not delay an airway intervention that has become necessary.
Apply it
After initiation of bilevel ventilation for COPD, a patient becomes somnolent, develops weaker respiratory effort, and has a falling pH. Escalate airway management rather than repeatedly adjusting the mask while deterioration continues.
Common pitfall: A well-sealed mask and acceptable oxygen saturation do not establish success if ventilation, consciousness, or the ability to protect the airway is worsening.
Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure
18.Why can positive-pressure support help acute cardiogenic pulmonary edema?
Continuous positive airway pressure or bilevel noninvasive ventilation can improve respiratory distress in acute cardiogenic pulmonary edema. Positive airway pressure improves aeration and reduces respiratory workload, while changes in intrathoracic pressure can favorably affect left ventricular loading. These benefits do not eliminate the need to treat the cardiac cause. Assess blood pressure, airway protection, and clinical stability, because the evidence supporting noninvasive support does not make it appropriate for every patient with shock or altered consciousness.
Apply it
A hypertensive, alert patient develops acute pulmonary edema with severe respiratory distress. Add appropriate noninvasive positive-pressure support while treating the cardiac precipitant and monitoring for changes in perfusion and respiratory status.
Common pitfall: The favorable role of noninvasive support in cardiogenic edema cannot be generalized to every cause of acute hypoxemic respiratory failure or every unstable patient.
Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure
19.How does cardiac dysfunction modify vasopressor and inotrope selection in septic shock?
Norepinephrine remains the usual first-line vasopressor in adult septic shock. The 2026 Surviving Sepsis Campaign separately suggests either norepinephrine or epinephrine as initial vasopressor therapy when septic shock includes concomitant cardiac dysfunction. Persistent hypoperfusion despite adequate volume status and arterial pressure requires assessment of cardiac function and output. When cardiac dysfunction contributes, the guideline suggests adding dobutamine to norepinephrine or using epinephrine alone. Blood pressure restoration does not ensure adequate forward flow. Continue antimicrobial treatment, source control, and repeated assessment of perfusion.
Apply it
A patient receiving norepinephrine has adequate arterial pressure but persistent poor perfusion. Echocardiography shows depressed cardiac function. Assess output and consider inotropic support rather than assuming that additional vasoconstriction or fluid will correct the problem.
Common pitfall: Do not treat norepinephrine as the only acceptable initial agent in septic shock with cardiac dysfunction, or use a normal arterial pressure as proof that tissue perfusion has recovered.
20.Why does ARDS protection require more than correcting oxygen saturation?
ARDS creates a heterogeneous lung in which the remaining aerated regions may receive a disproportionate share of each breath. Ventilation can therefore worsen injury through excessive stress even when oxygenation appears acceptable. Protective management combines low tidal volume, plateau-pressure limitation, appropriate PEEP, and prone positioning when indicated. Gas exchange remains important, but pursuing normal values with injurious settings can defeat the purpose of support. Judge the entire ventilatory strategy rather than one reassuring monitor value.
Apply it
An ARDS patient has SpO2 of 96% while receiving a large tidal volume and plateau pressure above the protective target. Reduce excessive mechanical stress and reassess gas exchange rather than accepting the settings because oxygenation looks normal.
Common pitfall: A normal saturation cannot reveal excessive alveolar stress; oxygen delivery and ventilator-induced injury are related but distinct considerations during respiratory support in ARDS.
ATS/ESICM/SCCM Guideline: Mechanical Ventilation in Adult Patients with ARDS · ATS 2024 Clinical Year in Review
Diffuse Parenchymal Lung Disease (DPLD)10%
21.Which CT features support a usual interstitial pneumonia pattern?
A usual interstitial pneumonia pattern on high-resolution CT typically has subpleural and basal predominance, reticulation, and honeycombing, with or without peripheral traction bronchiectasis or bronchiolectasis. The overall distribution and absence of features suggesting an alternative diagnosis matter. Honeycombing represents clustered cystic air spaces in a fibrotic context rather than any isolated lung cyst. Recognizing the pattern guides diagnostic confidence and the need for additional evaluation, but it does not independently identify the cause.
Apply it
An older adult has progressive exertional dyspnea and basal crackles. CT shows subpleural basal reticulation, traction bronchiectasis, and honeycombing. Identify a UIP pattern, then investigate whether the clinical setting supports idiopathic pulmonary fibrosis.
Common pitfall: Do not equate any reticulation or scattered cysts with definite UIP; distribution, associated fibrosis, and findings suggesting another diagnosis determine the imaging classification.
Diagnosis of Idiopathic Pulmonary Fibrosis: Official ATS/ERS/JRS/ALAT Guideline, 2018
22.Why does a UIP pattern not automatically establish idiopathic pulmonary fibrosis?
UIP describes a radiologic or histopathologic pattern, whereas idiopathic pulmonary fibrosis is a clinical diagnosis requiring exclusion of known causes of interstitial lung disease. Connective tissue disease, relevant exposures, and medication toxicity can produce fibrotic disease that changes the diagnostic interpretation. A structured history and appropriate evaluation therefore remain necessary even when imaging is highly characteristic. The word idiopathic carries a causal requirement; it cannot be assigned solely from an image label.
Apply it
A patient with UIP-pattern fibrosis also reports inflammatory joint symptoms and longstanding Raynaud phenomenon. Investigate a systemic inflammatory cause before assigning idiopathic pulmonary fibrosis, because the imaging pattern does not settle the underlying diagnosis.
Common pitfall: A confident radiology report can establish a pattern without establishing its cause; skipping exposure, medication, and systemic disease assessment can misclassify the entire illness.
Diagnosis of Idiopathic Pulmonary Fibrosis: Official ATS/ERS/JRS/ALAT Guideline, 2018
23.When can additional lung tissue add value in suspected pulmonary fibrosis?
The value of lung biopsy depends on diagnostic uncertainty, procedural risk, and whether tissue could change management. The 2018 IPF diagnostic guideline distinguishes a characteristic UIP CT pattern from less definitive patterns and emphasizes multidisciplinary interpretation. A high-confidence diagnosis in an appropriate clinical setting may avoid surgical biopsy. Conversely, uncertain imaging or a plausible competing disease may justify further evaluation. The correct decision integrates clinical history and imaging rather than treating biopsy as a mandatory final step.
Apply it
A frail patient has characteristic UIP imaging and no identified alternative cause after evaluation. Discuss the case multidisciplinary rather than ordering surgical biopsy automatically; weigh whether any likely tissue result would alter the decision.
Common pitfall: Biopsy provides information at a cost; obtaining tissue merely to confirm an already secure diagnosis can add procedural risk without a meaningful clinical benefit.
Diagnosis of Idiopathic Pulmonary Fibrosis: Official ATS/ERS/JRS/ALAT Guideline, 2018
24.What does antigen-specific serum IgG mean in suspected hypersensitivity pneumonitis?
Antigen-specific serum IgG supports prior exposure or sensitization to a potential antigen. A positive result does not establish that the exposure caused the patient's interstitial lung disease, and a negative result does not reliably exclude hypersensitivity pneumonitis. Available testing does not encompass every relevant antigen. Use the result to refine exposure investigation and integrate it with CT findings, bronchoalveolar lavage, and pathology when needed. The clinical question is causal relevance, not simply whether an antibody is detectable.
Apply it
A patient with fibrotic lung disease has positive bird-specific IgG but no clear exposure history. Investigate household, occupational, and indirect bird-related exposures while reviewing imaging; do not diagnose hypersensitivity pneumonitis from the antibody alone.
Common pitfall: A positive exposure marker is tempting diagnostic closure, but sensitization can occur without disease and must be connected to the patient's actual lung findings.
Diagnosis of Hypersensitivity Pneumonitis in Adults: Official ATS/JRS/ALAT Guideline, 2020
25.How are the main diagnostic domains of hypersensitivity pneumonitis combined?
Hypersensitivity pneumonitis diagnosis integrates exposure assessment, imaging pattern, and bronchoalveolar lavage or histopathologic findings. These domains contribute different information: a plausible antigen identifies opportunity, CT characterizes the lung response, and lymphocytosis or tissue may strengthen or redirect the interpretation. Fibrotic disease can be particularly difficult to distinguish from other interstitial disorders. Diagnostic confidence reflects concordance across domains, often through multidisciplinary discussion, rather than a single universally decisive laboratory test or imaging feature.
Apply it
A bird keeper has fibrosis, expiratory air trapping, and lavage lymphocytosis. Combine these findings with the exposure history to assess diagnostic confidence; the same CT finding without the supporting context would be less conclusive.
Common pitfall: Air trapping alone is not specific for hypersensitivity pneumonitis, and failure to identify an antigen does not by itself exclude the disease from consideration.
Diagnosis of Hypersensitivity Pneumonitis in Adults: Official ATS/JRS/ALAT Guideline, 2020
26.Which systemic clues should change the evaluation of apparently idiopathic ILD?
Interstitial lung disease may precede a fully recognized connective tissue disease. Symptoms such as inflammatory arthritis, Raynaud phenomenon, characteristic skin changes, or proximal muscle weakness can redirect evaluation toward systemic inflammatory disease. The IPF diagnostic approach requires consideration of connective tissue disease rather than relying on pulmonary findings alone. Serologic results require clinical interpretation: an isolated positive antibody does not necessarily establish a systemic diagnosis, while a meaningful symptom cluster can justify coordinated specialist assessment.
Apply it
A patient referred for fibrotic ILD reports difficulty rising from a chair and new hand changes. Expand the history, examination, and targeted systemic evaluation rather than accepting an idiopathic label based only on chest imaging.
Common pitfall: Neither a negative general review nor an isolated positive antibody settles the question; connect specific extrapulmonary findings with appropriate testing and the lung phenotype.
Diagnosis of Idiopathic Pulmonary Fibrosis: Official ATS/ERS/JRS/ALAT Guideline, 2018
Sleep Medicine, Neuromuscular and Skeletal10%
27.Which adults are appropriate candidates for home sleep apnea testing?
Home sleep apnea testing can diagnose obstructive sleep apnea in an uncomplicated adult with symptoms indicating increased risk of moderate-to-severe disease, following a comprehensive sleep evaluation. It is not a universal substitute for polysomnography. The selected device and recording must be technically adequate, and results require clinical interpretation. Significant comorbidity or concern for other sleep-related breathing disorders changes the testing strategy because limited home measurements may not characterize the relevant physiology.
Apply it
An otherwise uncomplicated adult has habitual loud snoring, witnessed apneas, and prominent daytime sleepiness. After a comprehensive evaluation, a technically adequate home sleep apnea test can be an appropriate diagnostic option.
Common pitfall: A screening questionnaire estimates risk but does not diagnose obstructive sleep apnea; testing choices must also account for comorbidity and competing sleep disorders.
AASM Clinical Practice Guideline: Diagnostic Testing for Adult Obstructive Sleep Apnea
28.What follows a negative home sleep apnea test when suspicion remains high?
A negative, inconclusive, or technically inadequate home sleep apnea test should be followed by polysomnography when evaluating suspected obstructive sleep apnea. Home testing is a limited-channel diagnostic study. Most devices lack electroencephalographic sleep staging, so monitoring time can exceed actual sleep time and dilute the respiratory event index. Some arousal-associated events may also be missed. These limitations can produce underestimation despite an apparently adequate recording. Interpret the result alongside the clinical history rather than treating a negative result as definitive exclusion.
Apply it
A sleepy adult with witnessed apneas has a negative home study but reports being awake for much of the recording. Arrange laboratory polysomnography to resolve the discrepancy.
Common pitfall: Do not manually replace monitoring time with a patient's estimated sleep duration to create a definitive index. Obtain an appropriate diagnostic study.
AASM Clinical Practice Guideline: Diagnostic Testing for Adult Obstructive Sleep Apnea
29.When is polysomnography preferable to home testing?
Polysomnography is preferred when suspected sleep apnea occurs with significant cardiorespiratory disease, possible respiratory muscle weakness, awake hypoventilation or suspected sleep-related hypoventilation, chronic opioid use, previous stroke, or severe insomnia. These settings increase the chance that limited home measurements will miss or misclassify relevant abnormalities. The decision reflects the need to characterize physiology beyond straightforward obstructive events. A high probability of obstructive apnea does not erase the importance of a coexisting ventilatory disorder.
Apply it
An adult with progressive neuromuscular weakness reports morning headaches and disrupted sleep. Select laboratory polysomnography rather than routine home apnea testing because respiratory muscle impairment raises concern for sleep-related hypoventilation.
Common pitfall: Convenience does not make home testing adequate for every patient; the suspected mechanism and associated disease determine whether broader laboratory monitoring is needed.
AASM Clinical Practice Guideline: Diagnostic Testing for Adult Obstructive Sleep Apnea
30.What establishes obesity hypoventilation syndrome?
Obesity hypoventilation syndrome requires obesity, sleep-disordered breathing, and awake daytime arterial hypercapnia, conventionally PaCO2 at least 45 mm Hg, after excluding other causes of hypoventilation. Obesity alone and obstructive sleep apnea alone do not establish the syndrome. Consider competing explanations such as neuromuscular disease, chest-wall disorders, medication effects, or substantial obstructive lung disease. Recognizing persistent daytime ventilatory failure changes the evaluation beyond counting nocturnal obstructive events.
Apply it
An adult with marked obesity and sleep apnea has daytime PaCO2 of 51 mm Hg. Review medications and evaluate alternative ventilatory disorders before concluding that the combination represents obesity hypoventilation syndrome.
Common pitfall: Nocturnal desaturation is not a substitute for demonstrating awake hypercapnia; oxygenation abnormalities and inadequate alveolar ventilation are related but distinct findings requiring assessment.
31.How does serum bicarbonate help screen for obesity hypoventilation?
Chronic carbon dioxide retention stimulates renal bicarbonate retention, making serum bicarbonate a useful screening clue for obesity hypoventilation. In a patient with low or moderate suspicion, bicarbonate below 27 mmol/L makes the syndrome unlikely. A value at or above 27 mmol/L calls for assessment of PaCO2 rather than establishing the diagnosis. When suspicion is high, directly measure arterial carbon dioxide. Other acid-base processes can also raise bicarbonate and must be considered.
Apply it
An obese adult with sleep-disordered breathing has bicarbonate of 30 mmol/L. Obtain an arterial blood gas to assess awake hypercapnia, while reviewing diuretic use and other explanations for an elevated bicarbonate concentration.
Common pitfall: An elevated bicarbonate is a screening signal, not proof of hypoventilation; metabolic alkalosis and medication effects can produce the same laboratory finding in practice.
32.How should positive airway pressure be selected and followed in adult OSA?
AASM recommends positive airway pressure for objectively diagnosed OSA with excessive sleepiness. Either CPAP or auto-adjusting PAP is recommended for ongoing treatment. In adults without significant comorbidities, initiation can use home APAP or laboratory titration; this pathway should not be generalized to hypoventilation or complex cardiorespiratory disease. Routine uncomplicated OSA usually does not require bilevel PAP. Education, early troubleshooting, and review of objective usage and efficacy data are part of treatment. These recommendations come from the [AASM PAP treatment guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/).
Apply it
A sleepy adult with confirmed uncomplicated OSA starts APAP. At early follow-up, review hours of use, residual events, symptoms, and mask difficulties before declaring treatment ineffective.
Common pitfall: Prescribing a device does not establish effective treatment. Persistent symptoms require assessment of actual use and efficacy, and hypoventilation requires a separate ventilatory evaluation.
Epidemiology2%
33.How do sensitivity and positive predictive value answer different questions?
Sensitivity is the proportion of people with disease who test positive: true positives divided by true positives plus false negatives. Positive predictive value is the proportion of positive tests that represent disease: true positives divided by all positive results. Predictive value depends strongly on disease prevalence in the tested population. Consequently, a sensitive test can still generate many false-positive diagnoses in a low-prevalence setting. Always identify the denominator before calculating or interpreting a diagnostic performance measure.
Apply it
Among 100 people with disease, a test identifies 90; among 900 without disease, 90 test positive. Sensitivity is 90%, but positive predictive value is 90 divided by 180, or 50%.
Common pitfall: Using all positive tests as the denominator calculates positive predictive value, not sensitivity; confusing the two changes the clinical meaning of the result substantially.
Infections12%
34.How do an acid-fast smear and an IGRA differ in suspected tuberculosis?
An acid-fast sputum smear detects acid-fast organisms but does not distinguish Mycobacterium tuberculosis from nontuberculous mycobacteria. Negative microscopy does not exclude pulmonary tuberculosis. An interferon-gamma release assay measures an immune response indicating tuberculosis infection and cannot distinguish latent infection from active disease. Symptoms, imaging, organism-specific molecular testing, and culture address disease activity and organism identification. A positive IGRA in a symptomatic patient therefore requires evaluation for active disease before considering a latent-infection regimen.
Apply it
A patient has cough, an abnormal radiograph, and a positive IGRA. Obtain appropriate respiratory testing for active tuberculosis rather than treating the immune assay as proof of latent infection.
Common pitfall: Neither acid-fast staining nor an immune response test independently establishes active pulmonary tuberculosis. Each method answers a different diagnostic question.
ATS/CDC/IDSA Guidelines: Diagnosis of Tuberculosis in Adults and Children
35.When does a negative tuberculosis NAAT fail to exclude disease?
In a smear-negative patient with intermediate or high clinical suspicion for pulmonary tuberculosis, a negative nucleic acid amplification test cannot reliably exclude disease. Low organism burden can limit detection. A positive result can provide useful presumptive evidence, but interpretation differs with smear status and pretest probability. Continue culture-based investigation and clinical assessment when the presentation remains concerning. Test performance does not permit a single negative molecular result to erase a strongly suggestive syndrome.
Apply it
An immunocompromised patient has weight loss, compatible imaging, and tuberculosis exposure, but sputum smear and initial NAAT are negative. Pursue additional appropriate specimens and cultures rather than closing the diagnostic evaluation.
Common pitfall: The speed of molecular testing does not make a negative result definitive; its exclusionary value depends on specimen characteristics and the clinical probability of disease.
ATS/CDC/IDSA Guidelines: Diagnosis of Tuberculosis in Adults and Children
36.How should community-acquired pneumonia severity guide the site of care?
For adults with community-acquired pneumonia who do not have an immunocompromising condition, use the Pneumonia Severity Index together with clinical judgment to guide hospitalization. Severe CAP requires one major criterion—vasopressor-dependent septic shock or respiratory failure requiring invasive mechanical ventilation—or at least three minor criteria: respiratory rate ≥30/min, PaO2/FiO2 ≤250, multilobar infiltrates, confusion/disorientation, BUN ≥20 mg/dL, infection-related leukopenia below 4,000/µL excluding chemotherapy-induced leukopenia, platelets below 100,000/µL, core temperature below 36°C, or hypotension requiring aggressive fluid resuscitation. The [ATS/IDSA adult CAP guideline](https://www.idsociety.org/globalassets/idsa/practice-guidelines/community-acquired-pneumonia-in-adults/executive_summary.pdf) recommends direct ICU admission for either major criterion; minor criteria support decisions about higher-intensity care.
Apply it
An immunocompetent adult with pneumonia, new confusion, respiratory rate 34/min, and multilobar infiltrates meets three minor criteria and needs assessment for higher-intensity monitoring and treatment. Vasopressor-dependent septic shock independently meets a major criterion. A leukocyte count of 3,000/µL caused by chemotherapy must not be counted as infection-related leukopenia.
Common pitfall: Hospitalization prediction and recognition of severe CAP answer different questions. A low prognostic score cannot override clinically important hypoxemia, inability to take oral medication, or unsafe outpatient circumstances. This guideline addresses adult pneumonia acquired outside the hospital; its recommendations should not be applied unmodified to children, hospital-acquired pneumonia, or patients with immunocompromising conditions.
37.How should MAC isolation, disease criteria, and treatment be distinguished?
For the expectorated-sputum pathway, compatible NTM pulmonary disease generally requires the same species in at least two separate sputum cultures, together with symptoms, appropriate imaging, and exclusion of alternatives. Bronchoscopic and biopsy pathways have different microbiologic criteria. Obtain further sputum samples when the patient can produce them; bronchoscopy is not automatically required after one isolate. Meeting disease criteria still does not mandate treatment in every case. Progression, cavitation, smear positivity, symptoms, toxicity, and patient priorities determine the balance. Structured observation can be appropriate. When treating macrolide-susceptible MAC, use an appropriate multidrug regimen, generally at least three drugs including a macrolide and ethambutol, to protect against macrolide resistance.
Apply it
A mildly symptomatic sputum-producing patient has one MAC isolate and noncavitary nodular bronchiectatic changes. Obtain additional cultures before treatment or bronchoscopy; if criteria are later met, separately assess whether treatment or monitored observation is preferable.
Common pitfall: One isolate is not equivalent to established disease, and established disease is not equivalent to an automatic treatment decision. Macrolide monotherapy can compromise future treatment through resistance.
ATS/ERS/ESCMID/IDSA Guideline: Nontuberculous Mycobacterial Pulmonary Disease
38.Which empiric antibiotics fit hospitalized nonsevere community-acquired pneumonia?
For immunocompetent adults with nonsevere inpatient CAP without MRSA or Pseudomonas risk factors, recommended options include a beta-lactam plus a macrolide or a respiratory fluoroquinolone alone. Prior respiratory isolation and locally validated resistance risks guide broader coverage and cultures. Select the regimen after reviewing allergies, contraindications, and the clinical setting. Empiric treatment should be reassessed as microbiology and the clinical response become available. See the [ATS/IDSA CAP guideline](https://doi.org/10.1164/rccm.201908-1581ST).
Apply it
A hospitalized adult without resistant-pathogen risk factors can receive ceftriaxone plus azithromycin after assessment of allergies and contraindications. New microbiologic information may support narrowing or revising the regimen.
Common pitfall: Hospital contact alone does not justify automatic MRSA and antipseudomonal treatment. Broader coverage requires a relevant risk assessment rather than an assumption that every healthcare exposure predicts resistance.
39.When does aspiration require antibiotics or additional anaerobic coverage?
Aspiration pneumonitis is chemical injury after gastric aspiration and may improve over 24–48 hours with supportive care. Established aspiration pneumonia requires antibacterial treatment. The distinction depends on the event, subsequent course, and evidence of infection rather than the aspiration history alone. Additional anaerobic coverage beyond standard CAP therapy is not routinely suggested unless lung abscess or empyema is suspected. See the [ATS/IDSA CAP guideline](https://www.idsociety.org/globalassets/idsa/practice-guidelines/community-acquired-pneumonia-in-adults/executive_summary.pdf).
Apply it
A patient improving rapidly after witnessed gastric aspiration may need supportive care. Persistent infection with an abscess changes the antimicrobial decision and requires assessment of a suppurative complication.
Common pitfall: An aspiration history alone neither proves bacterial infection nor mandates additional anaerobic therapy. Reassess a worsening course rather than continuing to attribute every finding to the initial chemical injury.
40.Why can pleural infection remain likely despite a negative fluid culture?
Pleural fluid culture may be negative in genuine pleural infection, particularly after antibiotics or when sampling and organism recovery are limited. Interpret microbiology alongside pus, pleural pH, imaging, systemic illness, and the clinical course. Inoculating suitable fluid into blood culture bottles can improve microbiologic yield. A culture result identifies recoverable organisms; it is not a complete measure of whether the pleural space requires drainage. Source control decisions therefore cannot wait for culture positivity alone.
Apply it
A febrile patient has a loculated parapneumonic effusion with pleural pH 7.08, but culture remains negative after prior antibiotics. Treat the biochemical and imaging evidence as significant and arrange appropriate drainage.
Common pitfall: A sterile culture is not proof of a sterile pleural space; prior treatment and limited microbiologic sensitivity can conceal an infection requiring source control.
British Thoracic Society Pleural Disease Guideline and Pleural Procedures Statement, 2023
Neoplasia9.5%
41.Why does PET uptake not prove malignant mediastinal involvement?
Fluorodeoxyglucose uptake reflects increased glucose metabolism and can occur in inflammatory or infectious nodes as well as malignancy. PET therefore contributes to staging probability and biopsy planning rather than providing histologic confirmation. When mediastinal nodal status would change a potentially curative treatment strategy, tissue assessment may be necessary. Equally, a negative scan does not eliminate every setting requiring invasive staging. Interpret imaging in the context of tumor characteristics and the consequences of a staging error.
Apply it
A patient with apparently localized lung cancer has one PET-avid mediastinal node and a history of granulomatous infection. Obtain appropriate nodal tissue before excluding a potentially curative strategy based on metabolic imaging alone.
Common pitfall: High uptake is not a cancer-specific signature; converting PET positivity directly into definitive nodal stage can deny treatment on the basis of a false-positive result.
NCI: Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
42.How does endobronchial ultrasound contribute to lung cancer staging?
Endobronchial ultrasound-guided needle sampling can obtain tissue from accessible mediastinal and hilar lymph nodes, linking minimally invasive diagnosis with staging. Its value depends on which stations are sampled, specimen adequacy, and the clinical probability of nodal disease. A negative result is interpreted differently after systematic adequate sampling than after a limited or nondiagnostic procedure. Plan the investigation around the staging question, because confirming a primary lung lesion alone may leave the decisive nodal uncertainty unresolved.
Apply it
A patient has a lung mass and an enlarged accessible mediastinal node. Consider ultrasound-guided nodal sampling that could establish malignancy and nodal involvement together, rather than choosing a primary-mass biopsy that answers only diagnosis.
Common pitfall: A negative specimen from one node does not prove that the entire mediastinum is uninvolved; adequacy, sampled stations, and pretest suspicion still matter.
NCI: Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
43.Which biopsy target can establish both cancer diagnosis and the highest suspected stage?
A rational biopsy plan considers diagnostic yield, procedural risk, tissue requirements, and whether the result will establish the most consequential suspected disease extent. An accessible distant lesion or involved node may answer both diagnosis and staging, whereas sampling only the primary lesion may leave metastatic uncertainty. Suspicious imaging still requires appropriate interpretation because benign processes can mimic spread. Coordinate tissue acquisition with pathology needs so that a technically successful procedure also supports the intended treatment decision.
Apply it
Imaging shows a lung mass and a safely accessible suspicious distant lesion. Discuss whether sampling that lesion could establish both tumor identity and metastatic involvement before selecting a more invasive biopsy of the primary mass.
Common pitfall: The largest lesion is not automatically the best target; the most useful specimen answers the treatment-changing question with acceptable risk and adequate diagnostic tissue.
NCI: Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
44.How do anatomic resectability and physiologic operability differ?
Resectability concerns whether the cancer's anatomic extent permits an appropriate surgical approach. Operability concerns whether the patient can tolerate the proposed operation, considering cardiopulmonary reserve, comorbidity, and functional status. A localized tumor can be technically resectable in a patient whose procedural risk is unacceptable. Conversely, excellent physiology does not make advanced disease surgically curable. Treatment planning must answer both questions rather than using tumor stage or a single pulmonary measurement as the complete decision.
Apply it
A patient has localized lung cancer but severe exercise limitation and major cardiopulmonary disease. Assess physiologic fitness for the proposed resection while discussing other definitive options, rather than equating early stage with automatic surgical suitability.
Common pitfall: An acceptable resting oxygen saturation does not establish adequate operative reserve; the planned extent of resection and the patient's broader cardiopulmonary function remain important.
NCI: Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
45.Why can molecular testing change advanced NSCLC treatment?
Non-small cell lung cancer encompasses biologically distinct tumors. An EGFR exon 19 deletion or exon 21 L858R substitution identifies a sensitizing driver alteration and EGFR-directed treatment options, including osimertinib in the appropriate advanced-disease setting. EGFR tyrosine kinase inhibitors inhibit signaling that supports growth of these tumors. PD-L1 expression instead informs selection of immune checkpoint therapy in the appropriate molecular and clinical setting. PD-L1 testing does not replace driver testing: a high PD-L1 result does not identify or exclude an EGFR alteration, and a sensitizing driver can direct initial treatment toward targeted therapy despite PD-L1 expression. Interpret both results with histology, stage, and treatment setting.
Apply it
A patient with metastatic lung adenocarcinoma has high PD-L1 expression and an EGFR exon 19 deletion. The EGFR result identifies an EGFR-directed treatment pathway; high PD-L1 alone should not lead directly to immunotherapy selection. Coordinate adequate molecular and PD-L1 testing before committing to the initial systemic regimen.
Common pitfall: Smoking history cannot replace tumor testing. PD-L1 measures a different treatment-relevant feature from an oncogenic driver, so completing one assay does not make the other unnecessary.
NCI: Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
46.Which mechanisms explain major small-cell lung cancer paraneoplastic syndromes?
Small-cell lung cancer can cause endocrine and neurologic syndromes remote from direct tumor invasion. Inappropriate antidiuretic hormone activity can produce hypotonic hyponatremia with inappropriately concentrated urine. Ectopic ACTH can produce hypercortisolism, often with hypokalemia and metabolic alkalosis. Lambert–Eaton myasthenic syndrome reflects impaired presynaptic acetylcholine release and may cause proximal weakness with autonomic symptoms. Distinguishing these mechanisms directs evaluation of the systemic problem rather than attributing every abnormality to metastasis or treatment toxicity.
Apply it
A patient with small-cell lung cancer develops confusion, low serum osmolality, and concentrated urine without clinical volume depletion. Evaluate inappropriate antidiuretic hormone activity while excluding other causes of hypotonic hyponatremia and addressing symptom severity.
Common pitfall: Hyponatremia alone does not establish SIADH; volume status, renal function, medications, and endocrine alternatives must fit the interpretation before assigning a paraneoplastic cause.
NCI: Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
Pleural Disease5%
47.When does a parapneumonic effusion require drainage?
Frank pus establishes empyema and requires drainage. When fluid is not purulent, pleural pH helps assess complicated parapneumonic effusion: pH at or below 7.2 indicates high risk and supports intercostal drainage when there is safely accessible fluid. Intermediate results require integration with biochemical, imaging, and clinical findings. Collect and analyze pH appropriately because local anesthetic contamination and handling errors can alter the value. Antibiotics do not replace source control when drainage is indicated.
Apply it
A patient with pneumonia has an accessible pleural collection, persistent fever, and nonpurulent fluid with pH 7.10. Arrange drainage with antibiotics rather than waiting for frank pus or a positive culture to appear.
Common pitfall: A low pH should be interpreted in context and with reliable collection; malignant or inflammatory effusions can also be acidic without representing bacterial pleural infection.
British Thoracic Society Pleural Disease Guideline and Pleural Procedures Statement, 2023
48.Why does non-expandable lung change malignant effusion treatment?
Pleurodesis depends on apposition of visceral and parietal pleural surfaces. If the lung cannot adequately expand after fluid removal, that contact may not occur, reducing the chance of successful pleurodesis. An indwelling pleural catheter can provide ongoing symptom-directed drainage in malignant effusion with significant non-expandable lung. Assess symptom response to drainage, imaging, prognosis, and patient preferences. The therapeutic goal is durable relief with an approach suited to pleural mechanics and the patient's circumstances.
Apply it
A patient feels less breathless after malignant effusion drainage, but imaging shows substantial persistent non-expansion. Discuss an indwelling pleural catheter because repeated attempts at pleurodesis may fail without adequate contact between the pleural surfaces.
Common pitfall: Removing fluid does not guarantee that the lung can expand; choosing pleurodesis solely because the effusion is malignant ignores a necessary mechanical condition.
British Thoracic Society Pleural Disease Guideline and Pleural Procedures Statement, 2023
49.How does thoracic ultrasound improve pleural fluid procedures?
Thoracic ultrasound identifies the location and depth of pleural fluid and its relationship to the diaphragm, lung, and adjacent organs. This supports safer site selection for pleural aspiration and drainage and helps recognize loculations or a small accessible window. The assessment must correspond to the patient's procedural position and current anatomy. Imaging guidance does not eliminate the need for appropriate technique, consent, monitoring, and a clear indication for removing or sampling fluid.
Apply it
A patient with an elevated hemidiaphragm and a small effusion is referred for thoracentesis. Use ultrasound in the intended procedural position to determine whether a safe fluid pocket exists before introducing a needle.
Common pitfall: A distant skin mark obtained before repositioning can become misleading; procedural planning must reflect the current patient position and the actual accessible fluid collection.
British Thoracic Society Pleural Disease Guideline and Pleural Procedures Statement, 2023
Quality, Safety, and Complications5%
50.How does root cause analysis turn an adverse event into a systems investigation?
Root cause analysis retrospectively examines a serious adverse event to identify contributing system vulnerabilities rather than ending with individual blame. Reconstructing the event, interviewing participants, and examining workflow can reveal how communication, equipment, staffing, or process design aligned to permit harm. The analysis is useful only when it produces effective corrective actions and follow-up. Strong changes reduce reliance on memory or vigilance, while education alone may leave the original vulnerability largely intact.
Apply it
After a wrong-side pleural procedure, a team reconstructs consent, imaging review, site marking, and time-out failures. It redesigns the verification process and measures compliance rather than simply reminding clinicians to be more careful.
Common pitfall: Naming the final operator's mistake is not a complete causal analysis; effective prevention requires understanding why the surrounding system allowed that mistake to reach the patient.
51.When should failure mode and effects analysis be used?
Failure mode and effects analysis prospectively examines a process before harm occurs. A multidisciplinary team maps the steps, identifies ways each step could fail, considers consequences and detection, and prioritizes improvements. This differs from reconstructing a completed adverse event. It is particularly useful when introducing a new device or workflow with foreseeable hazards. The intended output is a safer process with tested safeguards, not merely a catalog of everything that might go wrong.
Apply it
Before launching a new bronchoscopy sedation workflow, a team maps medication selection, labeling, monitoring, and rescue steps. It identifies high-risk failure points and installs safeguards before the first patient undergoes the revised process.
Common pitfall: Prospective risk scoring does not itself prevent harm; the team must implement practical changes and verify that the redesigned workflow works under real conditions.
52.Why is home oxygen education a fire-prevention intervention?
Oxygen supports combustion and can make materials ignite more readily and burn more intensely. Home oxygen education must therefore address smoking, open flames, sparks, equipment handling, and safe storage according to device instructions. The hazard is not limited to the patient actively smoking while wearing a cannula; nearby ignition sources also matter. Teach-back and household involvement help connect the prescription to daily behavior, while equipment review addresses practical obstacles to safe use.
Apply it
A patient using home oxygen says a family member smokes beside the concentrator. Explain the oxygen-enriched fire hazard, establish a smoke-free use environment, and review household ignition sources with the patient and caregiver.
Common pitfall: Oxygen is not itself a fuel, but that distinction does not make it safe near flames; its support of combustion creates a serious household hazard.
Transplantation2%
53.What magnitude and duration of decline define chronic lung allograft dysfunction?
ISHLT defines CLAD by a persistent FEV1 decline of at least 20% from the reference baseline, calculated as the mean of the two best postoperative FEV1 measurements obtained more than three weeks apart. An initial decline meeting this threshold raises possible CLAD and triggers investigation. Repeat impairment at least three weeks later, after appropriate treatment of secondary causes, supports probable CLAD. Persistence for three months from the initial qualifying measurement supports confirmed CLAD. Evaluate and treat competing causes such as infection, acute rejection, airway stenosis, and aspiration throughout this period; confirmation does not justify passive waiting.
Apply it
The two best postoperative FEV1 values are 3.0 and 3.2 L, measured more than three weeks apart. Baseline is 3.1 L; FEV1 at or below 2.48 L meets the 20% decline threshold. Serial measurements and evaluation determine possible, probable, or confirmed CLAD.
Common pitfall: Use the individual's postoperative reference baseline, not 80% of population-predicted FEV1. A single qualifying decline prompts evaluation but does not establish confirmed CLAD.
Vascular Diseases6%
54.How do V/Q scanning, vascular imaging, and catheterization contribute to CTEPH diagnosis?
Persistent organized thromboembolic obstruction can increase pulmonary vascular resistance and load the right ventricle. In unexplained pulmonary hypertension or persistent symptoms after pulmonary embolism, V/Q scanning screens for a chronic thromboembolic mechanism. Mismatched segmental perfusion defects indicate reduced blood flow despite preserved ventilation and prompt further evaluation. Anatomic vascular imaging characterizes obstructive lesions, while right-heart catheterization confirms and measures pulmonary hypertension. A positive screening scan alone does not establish the complete syndrome or determine operability.
Apply it
A patient has progressive dyspnea after pulmonary embolism and echocardiographic evidence suggesting pulmonary hypertension. Obtain V/Q scanning; a suggestive result warrants specialist vascular imaging and hemodynamic assessment.
Common pitfall: An earlier CT examination for acute embolism does not automatically settle a later CTEPH evaluation. Screening, anatomic characterization, and hemodynamic confirmation answer different questions.
ATS Patient Information Series: Chronic Thromboembolic Pulmonary Hypertension, Part 1
55.How should pretest probability guide testing for acute pulmonary embolism?
Estimate clinical pretest probability before selecting a test. In an appropriate low- or intermediate-probability population, a negative high-sensitivity D-dimer can exclude PE without imaging. A positive D-dimer does not diagnose PE and requires appropriate imaging. High clinical probability favors an imaging-first strategy, generally CT pulmonary angiography, rather than reliance on D-dimer exclusion. V/Q scanning is an alternative when appropriate to the patient's circumstances. These principles are set out in the [ASH VTE diagnosis guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC6258916/).
Apply it
A patient with low clinical probability and a negative high-sensitivity D-dimer can avoid CT imaging. A patient with high probability should proceed to appropriate imaging rather than using the same exclusion strategy.
Common pitfall: D-dimer specificity is limited. A positive result changes the testing pathway but does not establish a thrombus or justify labeling the patient with PE.
56.When does acute pulmonary embolism require more than anticoagulation?
Anticoagulation is the foundation of treatment when not contraindicated. Hemodynamic compromise or evolving cardiopulmonary failure requires urgent assessment for reperfusion and circulatory support. In a stable patient, right ventricular dysfunction or biomarker elevation warrants risk assessment and monitoring but does not automatically require systemic thrombolysis. Its potential benefit must be weighed against major bleeding, including intracranial hemorrhage; the 2026 guideline identifies uncertain benefit for systemic thrombolysis in selected patients with elevated severity, RV dysfunction, and biomarker abnormalities without established failure. See the [2026 multisociety acute PE guideline](https://www.jacc.org/doi/10.1016/j.jacc.2025.11.005).
Apply it
A normotensive patient with PE and RV strain receives anticoagulation and monitored care. New hypotension or evidence of worsening perfusion triggers urgent reassessment for reperfusion rather than routine continuation of the original plan.
Common pitfall: Neither clot size nor RV strain alone determines treatment intensity. Reassess perfusion, clinical trajectory, and bleeding risk.
Pulmonary Disease Blueprint: Certification Examination (CERT), April 2026
57.How does specialist assessment guide CTEPH treatment selection?
Confirmed chronic thromboembolic pulmonary hypertension requires lifelong therapeutic anticoagulation and multidisciplinary treatment selection by an experienced CTEPH team. Pulmonary endarterectomy is the treatment of choice for surgically accessible organized obstruction when the operative benefit outweighs risk. Balloon pulmonary angioplasty is recommended for technically inoperable disease or residual pulmonary hypertension after endarterectomy when distal obstructive lesions are amenable to angioplasty. Riociguat is recommended for symptomatic inoperable CTEPH or persistent/recurrent pulmonary hypertension after surgery. These pathways can be combined according to anatomy and physiology, as described in the [2022 ESC/ERS pulmonary hypertension guideline](https://publications.ersnet.org/content/erj/early/2022/08/25/1399300300879-2022).
Apply it
A patient with accessible proximal obstruction and acceptable operative risk should undergo evaluation for endarterectomy. A patient with technically inoperable distal lesions may be considered for balloon pulmonary angioplasty and medical therapy. Persistent symptomatic pulmonary hypertension after surgery warrants reassessment for residual treatable obstruction and consideration of riociguat; anticoagulation continues throughout these pathways.
Common pitfall: Anticoagulation prevents recurrent thromboembolism but does not remove established organized obstruction. Neither a screening V/Q scan nor the magnitude of pulmonary pressure elevation establishes operability. Distal disease should prompt expert review rather than automatic assignment to medication alone, because procedural suitability depends on lesion anatomy and center expertise.
ATS Patient Information Series: Chronic Thromboembolic Pulmonary Hypertension, Part 1
Respiratory Physiology and Pulmonary Symptoms4%
58.Why does a substantial right-to-left shunt respond poorly to supplemental oxygen?
A right-to-left shunt allows blood to reach the systemic arterial circulation without adequate exposure to ventilated alveoli. Increasing inspired oxygen improves oxygen content in blood traversing ventilated regions but cannot directly oxygenate blood bypassing them. The mixed arterial result therefore shows a limited response when the shunted fraction is substantial. This differs from many low ventilation-perfusion states, which often improve more with oxygen. The physiologic distinction helps explain persistent hypoxemia despite a high inspired oxygen concentration.
Apply it
A patient with extensive air-space filling remains markedly hypoxemic despite a large increase in inspired oxygen. Consider a substantial intrapulmonary shunt component rather than assuming the oxygen delivery device alone explains the poor response.
Common pitfall: Poor oxygen response suggests shunt physiology but does not identify its cause; intracardiac pathways, vascular abnormalities, and nonventilated perfused lung require different subsequent evaluations.
59.What confirms restriction when FVC is reduced with a preserved FEV1/FVC ratio?
A restrictive ventilatory impairment requires total lung capacity below the lower limit of normal, conventionally the fifth percentile of an appropriate reference distribution. Reduced FVC with a preserved FEV1/FVC ratio suggests possible restriction but does not confirm it. With normal TLC, it may represent a nonspecific pattern; air trapping or inadequate performance can also reduce FVC. Review test quality and measure lung volumes. Diffusing capacity evaluates gas transfer and complements mechanical measurements but cannot substitute for TLC. See the [ERS/ATS technical standard on lung-function interpretation](https://publications.ersnet.org/content/erj/60/1/2101499).
Apply it
A patient has FVC below the lower limit of normal and a preserved ratio, but normal TLC with increased residual volume. Interpret the reduced FVC in relation to air trapping rather than diagnosing restriction.
Common pitfall: A fixed percentage of predicted FVC is not the defining criterion for restriction. Confirm reduced TLC using an appropriate lower limit of normal.
Occupational and Environmental Diseases2%
60.Why does silica exposure change both fibrosis and tuberculosis assessment?
Respirable crystalline silica exposure can cause silicosis and is associated with increased tuberculosis risk, as well as other serious disease. Obtain an occupational history that identifies tasks such as cutting, grinding, or drilling silica-containing material rather than relying only on job titles. New symptoms in an exposed worker may represent pneumoconiosis, infection, or another silica-associated condition. Recognizing the exposure therefore changes both causal evaluation and the threshold for investigating tuberculosis when symptoms or imaging are concerning.
Apply it
An engineered-stone worker develops weight loss, cough, and nodular lung abnormalities. Investigate silica-related disease and tuberculosis in parallel rather than assuming the occupational explanation makes infection unnecessary to consider in the diagnostic workup.
Common pitfall: A plausible exposure diagnosis does not exclude a second process; silica-associated fibrosis and tuberculosis can coexist and require separate assessment of the clinical evidence.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Prioritize obstructive disease and critical care: together they account for 32.5% of the typical blueprint, with emphasis on objective diagnosis, stable pharmacotherapy, and consequential ventilation decisions.
- Separate test results from diagnoses: sensitization from hypersensitivity pneumonitis, PET uptake from malignant staging, NTM isolation from disease, and screening from confirmation.
- Practise interpreting pH with PaCO2, selecting predicted-weight tidal volumes, and distinguishing oxygenation failure from ventilatory failure.
- Choose sleep testing according to comorbidity and suspected physiology, then connect confirmed OSA to appropriate PAP treatment and objective follow-up.
- Study common pneumonia decisions alongside mycobacterial interpretation: severity, empiric antibiotics, aspiration, and pleural source control.
- Connect cancer tissue acquisition to staging and treatment information rather than considering biopsy yield alone.
- Keep smaller domains active through recall of diagnostic denominators, pleural mechanics, systems safety, CLAD criteria, acute PE decisions, CTEPH assessment, and silica exposure.
- Use the complete official outline to extend study into infection syndromes, rare parenchymal diseases, nonrespiratory critical care, and other topics beyond these selective concepts.
A practical preparation plan
1. Build a blueprint-based study map
List all 13 official domains and their weights. Start with obstructive disease, critical care, infections, DPLD, sleep medicine, and neoplasia, while assigning recurring review time to every smaller domain.
2. Translate concepts into decisions
For each concept, state the mechanism, decisive cue, next action, and boundary. Practise explaining why a tempting alternative would be inappropriate for that particular patient.
3. Work the independent clinical questions
Answer the 20 questions before reading their explanations. Classify each error as a knowledge gap, misread clinical cue, incorrect denominator, or failure to distinguish screening from confirmation.
4. Revisit thresholds and mechanisms
Use flashcards to recall asthma variability, oxygen duration, ventilatory measurements, sleep-testing choices, microbiologic interpretation, CLAD criteria, and pleural drainage principles. Explain the reasoning aloud rather than memorizing isolated numbers.
5. Expand beyond the selective guide
Return to the April 2026 official outline and identify uncovered subtopics. Add case-based study from appropriate current clinical references, especially for broad infection, critical care, and uncommon disease categories.
6. Integrate competing explanations
Work mixed cases in which airway disease, infection, cardiac dysfunction, and pulmonary vascular disease can produce similar symptoms. Identify the finding that changes the next diagnostic or treatment decision.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM: Pulmonary Disease Certification Policies
- ABIM: Blueprints
- Pulmonary Disease Blueprint: Certification Examination (CERT), April 2026
- ABIM: Expanded Blueprints
- GINA 2026 Summary Guide for Asthma Management and Prevention
- Home Oxygen Therapy for Adults with Chronic Lung Disease: Official ATS Clinical Practice Guideline
- ATS Patient Information Series: Oxygen Therapy
- ATS/ESICM/SCCM Guideline: Mechanical Ventilation in Adult Patients with ARDS
- ATS 2024 Clinical Year in Review
- Official ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure
- Surviving Sepsis Campaign Adult Guidelines, 2026
- Diagnosis of Idiopathic Pulmonary Fibrosis: Official ATS/ERS/JRS/ALAT Guideline, 2018
- Diagnosis of Hypersensitivity Pneumonitis in Adults: Official ATS/JRS/ALAT Guideline, 2020
- AASM Clinical Practice Guideline: Diagnostic Testing for Adult Obstructive Sleep Apnea
- ATS Sleep Week: Obesity Hypoventilation Syndrome
- CDC Principles of Epidemiology: Lesson 5, Appendix A
- ATS/CDC/IDSA Guidelines: Diagnosis of Tuberculosis in Adults and Children
- ATS/ERS/ESCMID/IDSA Guideline: Nontuberculous Mycobacterial Pulmonary Disease
- NCI: Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
- NCI: Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
- British Thoracic Society Pleural Disease Guideline and Pleural Procedures Statement, 2023
- AHRQ PSNet: Root Cause Analysis
- AHRQ PSNet: Systems Approach
- ISHLT: Chronic Lung Allograft Dysfunction Consensus Report, 2019
- ATS Patient Information Series: Chronic Thromboembolic Pulmonary Hypertension, Part 1
- NHLBI: Pulmonary Function Tests
- CDC/NIOSH: Silica Symptoms and Medical Monitoring
- 2019_consensus_ishlt_clad.pdf
- Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline - PMC
- executive_summary.pdf
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism - PMC
- Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline - PMC
- eilo.pdf
- Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline - PMC
- diagnostic-testing-osa.pdf
- Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline - PMC
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.